All In Biotech

BLA 761125 · Novartis Pharms Corp

Beovu

Brolucizumab-Dbll · Intravitreal

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Jul 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 7, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

38

24 Phase 3, 1 recruiting

FAERS reports

3,648

2,878 serious, 246 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 26, 2026.

BEOVU ® is indicated for the treatment of: BEOVU is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Diabetic Macular Edema (DME) ( 1.2 ) 1.1 Neovascular (Wet) Age-related Macular Degeneration (AMD) 1.2 Diabetic Macular Edema (DME)

Mechanism: Brolucizumab is a human VEGF inhibitor. Brolucizumab binds to the three major isoforms of VEGF-A (e.g., VEGF 110 , VEGF 121 , and VEGF 165 ), thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, brolucizumab suppresses endothelial cell proliferation, neovascularization, and vascular permeability.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 27, 2022 Supplement 8 · Efficacy LetterLabel
  • Oct 7, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
1 products under this application
  • BEOVU · brolucizumab-dbll 6MG/0.05ML · INJECTABLE, INTRAVITREAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Brolucizumab" as an intervention, any sponsor and status, largest first.

All 38 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • visual impairment573
  • vitreous floaters558
  • vision blurred536
  • eye inflammation447
  • visual acuity reduced435
  • retinal vasculitis384
  • uveitis364
  • vitritis358
  • eye pain319
  • blindness247
  • anterior chamber cell233
  • ocular hyperaemia224

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20181
2019185
20201,252
2021845
2022461
2023341
2024310
2025168
202684

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Beovu (Brolucizumab-Dbll)

2024 spending

$317K

Beneficiaries

42

143 claims

Per beneficiary

$7,545

$39,859.50 per unit

View as table
YearSpending
2020$596,121
2021$546,835
2022$1,003,821
2023$602,256
2024$316,883

Part B: Beovu (Brolucizumab-Dbll) · HCPCS J0179

2024 spending

$13.6M

Beneficiaries

1,552

6,388 claims

Per beneficiary

$8,747

2024 ASP limit $328.68 per unit

View as table
YearSpending
2020$110,737,688
2021$66,538,896
2022$42,274,859
2023$21,308,128
2024$13,575,491

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 71 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.